On October 20-22 by the banks of Shanghai's Huangpu River, the 2026 Sustainable Global Leaders Conference returns once again. Nobel Prize and Turing Award winners will share their insights on the future and trends of technology on site, and the internet-famous professor who "rescues" people from anxiety and the era of involution — Macfarlane — will hold a live dialogue with Xiang Biao!
Limited seats available, first come first served. Let us jointly embark on the journey of sustainability! [Click to register] FANGZHOU JIANKE (06086) rose more than 6% intraday, and as of press time, its share price was up 4.82% at HK$0.87.
In the first half of 2026, FANGZHOU JIANKE recorded revenue of RMB 1.8245 billion (in the same currency unit throughout), a year-on-year increase of 22.2%; adjusted net profit reached RMB 18.708 million, up 6.4% year on year, maintaining a sound momentum of sustained profitability.
As of the latest disclosure date, the company has built a medical service network covering multiple departments by leveraging its broad and professional registered physician resources; its supply chain network covers more than 1,800 suppliers and more than 1,000 pharmaceutical enterprises, with economies of scale gradually emerging.
In the first half of 2026, the repurchase rate of FANGZHOU JIANKE's paid users reached as high as 89.2%.
Most notably, amid rapid technological iteration, FANGZHOU JIANKE has made forward-looking arrangements to embed AI technology into its business processes and has developed an AI product matrix based on the Xingshi large model, which is expected to solve the cost challenge of large-scale delivery of high-quality chronic disease services, turning full-cycle services from small-scale project practices into commercial businesses that can be popularized among tens of millions of users.
Comments